SurVaxM
- Generic Name
- SurVaxM
- Drug Type
- Biotech
- CAS Number
- 2416847-76-0
- Unique Ingredient Identifier
- HK7BJ56KSP
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Tumors
Phase 2
Not yet recruiting
- Conditions
- Malignant Solid NeoplasmDigestive System Neuroendocrine NeoplasmPancreatic Neuroendocrine NeoplasmLung Neuroendocrine Neoplasm
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyBiological: Incomplete Freund''s AdjuvantProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 132
- Registration Number
- NCT06202066
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
SurVaxM Expanded Access Protocol
- Conditions
- Glioblastoma
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT04802447
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Phase 2
Completed
- Conditions
- Recurrent Glioblastoma
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- David Peereboom
- Target Recruit Count
- 41
- Registration Number
- NCT04013672
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Phase 1
Recruiting
- Conditions
- Lung Atypical Carcinoid TumorMetastatic Pancreatic Neuroendocrine TumorLung Typical Carcinoid Tumor
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT03879694
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Phase 2
Active, not recruiting
- Conditions
- GlioblastomaGliosarcoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2015-05-28
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 66
- Registration Number
- NCT02455557
- Locations
- 🇺🇸
Dana-Farber Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Phase 1
Active, not recruiting
- Conditions
- Partial Response of Multiple Myeloma or Plasma Cell LeukemiaPlasma Cell Myeloma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 18
- Registration Number
- NCT02334865
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath